Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenuto archiviato il 2024-06-18

Embryonic Stem cell-based Novel Alternative Testing Strategies

Obiettivo

"ESNATS aims at developing a novel toxicity test platform based on embryonic stem cells (ESC), especially human ESC (hESC), to accelerate drug development, reduce R&D costs and propose a powerful alternative to animal tests (3 Rs). ESNATS will address current drug-testing shortcomings: - testing takes place late in the development cycle - animal test systems bear the risk of non-prediction due to inter-species variation - non-ESC assays rely on primary cells or cells of malignant origin that are hard-to-standardise and limited in regard to quantity, homogeneity and genetic diversity - existing assay systems based on primary animal cell lines do not reliably represent the physiological situation ESNATS will develop a battery of toxicity tests using hESC lines subjected to different standardised culture protocols. Tests will cover embryoid bodies in different developmental stages and differentiated derivatives including gamete and neuronal lineages, complemented with test systems for hepatic metabolism. Predictive toxicogenomics and proteomics markers will be identified. The individual tests will be integrated into an ""all-in-one"" test system. To enable future industrial use ESNATS will prepare automating and scaling up of hESC culture. The predictivity, quality and reproducibility of ESNATS will be evaluated in a proof of concept study. ESNATS benefits are to increase safety due to better predictivity of human test systems, to reduce, refine and replace animal tests, to lower testing cost, and to support medium/high throughput testing. ESNATS objectives will be achieved in a 5 year multi-disciplinary collaboration of leading European researchers in alternative testing, toxicology, ESC research, genomics, modelling, and automation. The consortium will also include representatives from regulatory bodies, the pharmaceutical industry and ethical advisors to provide guidance to ensure rapid applicability of the developed tests systems."

Campo scientifico

CORDIS classifica i progetti con EuroSciVoc, una tassonomia multilingue dei campi scientifici, attraverso un processo semi-automatico basato su tecniche NLP.

Parole chiave

Programma(i)

Argomento(i)

Invito a presentare proposte

FP7-HEALTH-2007-A
Vedi altri progetti per questo bando

Meccanismo di finanziamento

CP-IP - Large-scale integrating project

Coordinatore

KLINIKUM DER UNIVERSITAET ZU KOELN
Contributo UE
€ 2 825 955,59
Indirizzo
Kerpener Strasse 62
50937 Koeln
Germania

Mostra sulla mappa
Regione
Nordrhein-Westfalen Köln Köln, Kreisfreie Stadt
Tipo di attività
Higher or Secondary Education Establishments
Contatto amministrativo
Jutta Landvogt (Ms.)
Collegamenti
Costo totale
Nessun dato

Partecipanti (32)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 16 Luglio 2019

Il mio fascicolo

Permalink: https://cordis.europa.eu/project/id/201619/it

European Union, 2025